SCD and Hepatic steatosis: Among them, ω-3 PUFAs (18:3, 20:5, 22:6), which have shown beneficial effects on glycolipid metabolism dysfunction in animal experiments and clinics, are expected to become a new target drug for treating fatty liver.22,26 In parallel, B. theta did not affect the activity of stearoyl-CoA desaturase 1 (SCD1) (Figure 6i) but significantly increased the activity of fatty acid desaturase 1 (FADS1) (Figure 6j) and FADS2 (Figure 6k), which is consistent with the increased levels of C20:4 and C18:2 after B. theta treatment (Figure 6g,h).